Pfizer Agrees to Buy Seagen for $43 Billion
The New York drugmaker would pay $229 a share in cash for the biotech company and its pioneering cancer treatments.
Source link
The New York drugmaker would pay $229 a share in cash for the biotech company and its pioneering cancer treatments.
Source link